These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34036983)

  • 1. A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma.
    Zhang J; Qian XK; Song PF; Li XD; Wang AQ; Huo H; Yao JC; Zhang GM; Zou LW
    Anal Methods; 2021 Jun; 13(24):2671-2678. PubMed ID: 34036983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sensitive fluorescence assay of serum dipeptidyl peptidase IV activity to predict the suitability of its inhibitors in patients with type 2 diabetes mellitus.
    Zhang J; Zhu YD; Li CQ; Fan YM; Huo H; Sun CG; Zhou J; Sun L; Qian XK; Zou LW
    J Pharm Biomed Anal; 2024 Oct; 249():116382. PubMed ID: 39098293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly specific ratiometric two-photon fluorescent probe to detect dipeptidyl peptidase IV in plasma and living systems.
    Zou LW; Wang P; Qian XK; Feng L; Yu Y; Wang DD; Jin Q; Hou J; Liu ZH; Ge GB; Yang L
    Biosens Bioelectron; 2017 Apr; 90():283-289. PubMed ID: 27923191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.
    Davis JA; Singh S; Sethi S; Roy S; Mittra S; Rayasam G; Bansal V; Sattigeri J; Ray A
    Indian J Pharmacol; 2010 Aug; 42(4):229-33. PubMed ID: 20927248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum.
    Lammi C; Bollati C; Ferruzza S; Ranaldi G; Sambuy Y; Arnoldi A
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30104520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabrication of a water-soluble near-infrared fluorescent probe for selective detection and imaging of dipeptidyl peptidase IV in biological systems.
    Guo X; Mu S; Li J; Zhang Y; Liu X; Zhang H; Gao H
    J Mater Chem B; 2020 Jan; 8(4):767-775. PubMed ID: 31897456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
    Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Kobayashi M
    Drug Res (Stuttg); 2017 Jul; 67(7):396-403. PubMed ID: 28486736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus.
    Sromova L; Busek P; Posova H; Potockova J; Skrha P; Andel M; Sedo A
    Diabetes Res Clin Pract; 2016 Aug; 118():183-92. PubMed ID: 27388675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
    Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among
    Yang Y; Shi CY; Xie J; Dai JH; He SL; Tian Y
    Molecules; 2020 Jan; 25(1):. PubMed ID: 31906524
    [No Abstract]   [Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M; El-Metwally TH
    Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay.
    Vawhal PK; Jadhav SB; Kaushik S; Panigrahi KC; Nayak C; Urmee H; Khan SL; Siddiqui FA; Islam F; Eftekhari A; Alzahrani AR; Azlina MFN; Sarker MMR; Ibrahim IAA
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver.
    Asakura M; Fujii H; Atsuda K; Itoh T; Fujiwara R
    Drug Metab Dispos; 2015 Apr; 43(4):477-84. PubMed ID: 25597851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
    Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.